BEGIN:VCALENDAR VERSION:2.0 PRODID:-//Memento EPFL// BEGIN:VEVENT SUMMARY:EPFL BioE Talks SERIES "Metabolic Immunoengineering of CD8+ T-Cel ls Using Interleukin-10 for Enhanced Anti-Tumor Immunity" DTSTART:20201026T163000 DTEND:20201026T170000 DTSTAMP:20260510T105715Z UID:411a269d709c361c27d9e6bebba954d4f5af9750c5743701ab29833d CATEGORIES:Conferences - Seminars DESCRIPTION:Prof. Li Tang\, Institute of Bioengineering and Institute of M aterials Science & Engineering\, EPFL\, Lausanne (CH)\nWEEKLY EPFL BIOE TA LKS SERIES\n\n(note that this talk is number two of a double-feature semin ar - see details of the first talk here)\n\nAbstract:\nCancer immunotherap y represented by immune checkpoint blockades has achieved remarkable clini cal success. However\, an outstanding challenge is that a great majority o f patients fail to respond to this therapy. This is in part due to the fac t that tumour infiltrating lymphocytes (TILs) become exhausted and eventua lly incapable to control tumour progression. Among exhausted CD8+ TILs\, a subpopulation\, termed terminally exhausted CD8+ T-cells\, have superior cytotoxicity but largely reduced proliferation capacity\, and are known to be the direct contributors to the anti-tumour cytotoxicity. However\, thi s subpopulation do not respond to immune checkpoint blockades or most curr ent immunotherapies and are difficult to expand and maintain with their cy totoxicity. Here\, we show that a half-life extended interleukin (IL)-10/F c fusion protein directly expands the terminally exhausted CD8+ TILs and s ustains their cytotoxic functions through in vivo metabolic intervention\, leading to eradication of established solid tumours and durable cures in a majority of treated mice when combined with adoptive T-cell transfer imm unotherapies. We find that IL-10/Fc reprograms the metabolism of CD8+ T-ce lls by promoting oxidative phosphorylation leading to robust cell prolifer ation. Our results provide preclinical evidence that IL-10/Fc is a safe an d highly effective therapy that acts on a specific subset of CD8+ TILs dis tinct from those responding to immune checkpoint blockades and thus can co mplement and potentially synergize with many existing cancer immunotherapi es for markedly enhanced efficacy and response rates. We also identify a m echanism of pathway-specific metabolic regulation by which IL-10/Fc could expand CD8+ T-cells upon persistent antigen stimulation providing insight into the crucial role of metabolic profiles in anti-cancer immunity.\n\nBi o:\n\n Li Tang received his B.S. in Chemistry from Peking University in Ch ina in 2007\, and his Ph.D. in Materials Science and Engineering from Univ ersity of Illinois at Urbana-Champaign\, USA\, in 2012\, under the supervi sion of Prof. Jianjun Cheng. He was an Irvington Postdoctoral Fellow in th e laboratory of Prof. Darrell Irvine at Massachusetts Institute of Technol ogy during 2013-2016. He joined the faculty of Institute of Bioengineering \, and Institute of Materials Science & Engineering\, at École polytechni que fédérale de Lausanne (EPFL)\, Lausanne\, Switzerland\, as a Tenure-T rack Assistant Professor in 2016. His research focuses on modulating the immune system using smart biomaterials to develop novel vaccines and immu notherapies. Dr. Tang is the recipient of MIT Technology Review’s "Top 3 5 Innovators under Age 35" list of China region (2020)\, Biomaterials Scie nce Emerging Investigator (2019)\, European Research Council (ERC) startin g grant (2018)\, Nano Research Young Innovator Award (NR 45 under 45 in th e world) (2018)\, and Irvington Postdoctoral Fellowship from Cancer Resear ch Institute (2013).\n\n\n\nZoom link (with registration) for attending re motely: https://go.epfl.ch/EPFLBioETalks\n\n\nIMPORTANT NOTICE: due to res trictions resulting from the ongoing Covid-19 situation\, this seminar can be followed via Zoom web-streaming only\, following prior one-time regist ration through the link above. LOCATION:via Zoom web-streaming only\, due to Covid-19 situation https://g o.epfl.ch/EPFLBioETalks https://go.epfl.ch/EPFLBioETalks STATUS:CONFIRMED END:VEVENT END:VCALENDAR